Multicountry Distribution and Characterization of Extended-spectrum β-Lactamase-associated Gram-negative Bacteria From Bloodstream Infections in Sub-Saharan Africa. by Toy, Trevor et al.
S U P P L E M E N T  A R T I C L E S
Clinical Infectious Diseases
Distribution and Characterization of Bloodstream Infections Caused by ESBL Producing Gram-negative Bacteria • cid 2019:69 (Suppl 6) • S449
 
Correspondence: F.  Marks, Public Health, Access and Vaccine Epidemiology Unit, 
International Vaccine Institute, SNU Research Park, 1-Gwanak-ro, Gwanak-gu, Seoul 08826, 
Republic of Korea (fmarks@ivi.int).
Clinical Infectious Diseases®  2019;69(S6):S449–58
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/ciz450
Multicountry Distribution and Characterization of 
Extended-spectrum β-Lactamase–associated  
Gram-negative Bacteria From Bloodstream Infections in 
Sub-Saharan Africa
Trevor Toy,1 Gi Deok Pak,1 Trung Pham Duc,2 James I. Campbell,2 Muna Ahmed El Tayeb,3 Vera von Kalckreuth,1 Justin Im,1 Ursula Panzner,1  
Ligia Maria Cruz Espinoza,1 Daniel Eibach,4 Denise Myriam Dekker,4,5 Se Eun Park,1 Hyon Jin Jeon,1,6,  Frank Konings,1 Ondari D. Mogeni,1,7  
Leonard Cosmas,8 Morten Bjerregaard-Andersen,9,10 Nagla Gasmelseed,3,11 Julian T. Hertz,12,13 Anna Jaeger,4 Ralf Krumkamp,4 Benedikt Ley,1,14  
Kamala Thriemer,1,14 Leon Parfait Kabore,15 Aissatou Niang,16 Tiana Mirana Raminosoa,17 Emmanuel Sampo,18 Nimako Sarpong,19 Abdramane Soura,18  
Ellis Owusu-Dabo,19,20 Mekonnen Teferi,21 Biruk Yeshitela,21 Sven Poppert,22 Jürgen May,4,5 Jerome H. Kim,1 Yun Chon,1 Jin Kyung Park,1  
Abroaham Aseffa,21 Robert F. Breiman,7,23 Heidi Schütt-Gerowitt,1,24 Peter Aaby,9,10 Yaw Adu-Sarkodie,19,25 John A. Crump,12,13,26,27  
Raphaël Rakotozandrindrainy,17 Christian G. Meyer,28,29 Amy Gassama Sow,16,30 John D. Clemens,31,32,33 Thomas F. Wierzba,1 Stephen Baker,2,6 and  
Florian Marks1,6
1International Vaccine Institute, Seoul, South Korea; 2Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; 3Faculty of Medicine, University of Gezira, Wad Medani, Sudan; 4Bernhard 
Nocht Institute for Tropical Medicine, Hamburg, Germany; 5German Center for Infection Research, Hamburg-Borstel-Lübeck, Germany;  6Department of Medicine, Cambridge University, United 
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Background. Antimicrobial resistance (AMR) is a major global health concern, yet, there are noticeable gaps in AMR surveil-
lance data in regions such as sub-Saharan Africa. We aimed to measure the prevalence of extended-spectrum β-lactamase (ESBL) 
producing Gram-negative bacteria in bloodstream infections from 12 sentinel sites in sub-Saharan Africa.
Methods. Data were generated during the Typhoid Fever Surveillance in Africa Program (TSAP), in which standardized blood 
cultures were performed on febrile patients attending 12 health facilities in 9 sub-Saharan African countries between 2010 and 
2014. Pathogenic bloodstream isolates were identified at the sites and then subsequently confirmed at a central reference laboratory. 
Antimicrobial susceptibility testing, detection of ESBL production, and conventional multiplex polymerase chain reaction (PCR) 
testing for genes encoding for β-lactamase were performed on all pathogens.
Results. Five hundred and five pathogenic Gram-negative bloodstream isolates were isolated during the study period and avail-
able for further characterization. This included 423 Enterobacteriaceae. Phenotypically, 61 (12.1%) isolates exhibited ESBL activity, 
and genotypically, 47 (9.3%) yielded a PCR amplicon for at least one of the screened ESBL genes. Among specific Gram-negative 
isolates, 40 (45.5%) of 88 Klebsiella spp., 7 (5.7%) of 122 Escherichia coli, 6 (16.2%) of 37 Acinetobacter spp., and 2 (1.3%) of 159 of 
nontyphoidal Salmonella (NTS) showed phenotypic ESBL activity.
Conclusions. Our findings confirm the presence of ESBL production among pathogens causing bloodstream infections in 
sub-Saharan Africa. With few alternatives for managing ESBL-producing pathogens in the African setting, measures to control the 
development and proliferation of AMR organisms are urgently needed.
Keywords. extended-spectrum β-lactamase; ESBL; antibiotic resistance; antimicrobial resistance; Africa; surveillance.
Antimicrobial resistance (AMR) is a widely acknowledged 
global health issue of serious concern. AMR negatively affects 
both individual patients and healthcare systems because com-
munity- and hospital-acquired multidrug resistant (MDR) bac-
terial infections are associated with increased morbidity and 
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mortality and impose additional economic burden on health-
care systems [1–3].
Enterobacteriaceae are commonly associated with a range of 
infections and can rapidly develop resistance against a range of 
important broad-spectrum antimicrobials including extended-
spectrum cephalosporins [4]. The widespread empirical use 
of extended-spectrum β-lactam  antibiotics has inevitably led 
to the spread of Gram-negative bacteria expressing an array 
of β-lactamases, including extended-spectrum β-lactamases 
(ESBLs), AmpCs, and carbapenemases [5], leading to a prolif-
eration of organisms with broad-spectrum β-lactamase activity 
that threatens the future of the β-Lactam class in clinical care.
Although a consensus is lacking, functional classifica-
tion of ESBLs includes the β-lactamases that hydrolyze first-, 
second-, and third-generation cephalosporins, monobactams, 
and penicillins but not carbapenems [6]. However, unlike 
other β-lactamases, ESBLs are inhibited in vitro by β-lactamase 
inhibitors, such as clavulanic acid [3]. The current genotypic 
ESBL classification follows the Ambler classification scheme. 
ESBLs fall under classes A and D, whereas AmpCs fall under 
class  C, which groups enzymes according to the molecular 
characterization of enzyme types [7]. The Bush/Jacoby scheme 
groups enzymes in phenotypic functional groups according to 
distinctive β-lactamase substrates [7].
There is a substantial gap in the current AMR surveillance 
landscape in parts of sub-Saharan Africa, and limited diagnostic 
options often mean that infections are managed empirically [8]. 
Guidelines for empiric treatment of febrile illness and septi-
cemia such as the Integrated Management of Childhood Illness 
(IMCI)-based Pocket Book of Hospital Care for Children have 
not been revised in nearly 15  years, and clinicians practicing 
in resource-limited settings should take into consideration the 
most updated AMR data. Current AMR data from sub-Saharan 
Africa are also crucial for healthcare policy makers to priori-
tize resources for infection prevention and control. Utilizing 
data generated during the Typhoid Fever Surveillance in Africa 
Program (TSAP) [9], which performed standardized blood 
culture testing on febrile patients, we aimed to measure the 
burden of ESBL-producing Gram-negative bacteria associated 
with bloodstream infections in 12 sentinel sites in sub-Saharan 
Africa.
METHODS
Ethics
This study was approved by the Institutional Review Board 
(IRB) of the International Vaccine Institute as well as the IRBs 
and Ethics Committees of participating surveillance sites in the 
respective countries.
Study Sites
Samples for this investigation were collected during the TSAP 
study, of which the design, methods, and site characteristics 
are described elsewhere [10]. Briefly, clinical and demographic 
data were available for 12 sentinel in- and out-patient facilities 
in 9 sub-Saharan African countries (Burkina Faso, Ethiopia, 
Ghana, Guinea-Bissau, Kenya, Madagascar, Senegal, Sudan, 
and Tanzania). Outpatients of all ages with a current fever at 
the time of consultation (tympanic or axillary temperature of 
≥38.0°C or ≥37.5°C, respectively) were eligible for enrollment, 
as were inpatients with self-reported fever within the past 72 
hours or a current fever (tympanic or axillary temperature of 
≥38.0°C or ≥37.5°C, respectively). The exception was the Asante 
Akim North site in Ghana, which recruited children under the 
age of 15 years old. All participating sites followed standardized 
protocols and operating procedures to participate in bloodstream 
infection surveillance between January 2010 and September 
2013. Additionally, this study included bacterial isolates from 
consenting patients not enrolled in the TSAP incidence analyses.
Microbiological Procedures
Venous blood was collected from all consenting febrile patients 
enrolled into the study (5–10 mL for adults, 1–3 mL for chil-
dren) and inoculated into an aerobic blood culture bottle for 
on-site incubation in a continuously monitored blood culture 
instrument (BD BACTEC, Becton-Dickinson, Franklin Lakes, 
NJ, USA, or BacT/ALERT, BioMerieux, Marcy l’Etoile, France) 
with the exception of Sudan, where conventional incubation 
and subculturing was implemented.
Figure 1. Flow diagram of bloodstream infection Gram-negative bacterial 
isolates for ESBL analyses. Abbreviation: ESBL, extended-spectrum β-lactamase.
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Blood culture bottles were incubated at 37°C for 5 days and 
checked daily for bacterial growth or until flagged positive in the 
automated system. Subculturing was done onto sheep blood agar, 
MacConkey agar, and chocolate agar (all Oxoid, Basingstoke, 
United Kingdom). Plates were incubated at 37°C for 48 hours. 
Bacterial isolates were identified at the sites by the analytical pro-
file index (API 20E kits Bio-Mérieux), biochemical reactions for 
identification, and serogrouping if indicated. Salmonella serovar 
typing was performed at study sites using specific antisera ac-
cording to standardized operating procedures.
All bacterial isolates were stored at −80°C prior to transpor-
tation to one of the reference laboratories at the Bernhard Nocht 
Institute for Tropical Medicine, Hamburg, Germany and the 
Oxford University Clinical Research Unit, Ho Chi Minh City, 
Vietnam, for further characterization. As described elsewhere 
[10], a refined list of pathogenic and likely contaminant isolates 
including coagulase-negative Staphylococci, Corynebacterium 
spp., Bacillus spp. was inferred by previous publications and 
consultations with experienced clinical microbiologists.
Antimicrobial Susceptibility Testing
For pathogenic bloodstream isolates, antimicrobial suscepti-
bility of various antimicrobial agents was reconfirmed at the 
reference laboratory using the modified Kirby-Bauer disk dif-
fusion method and interpreted according to the most updated 
Clinical and Laboratory Standards Institute (CLSI) guidelines 
[11]. Phenotypic ESBL activity was suspected if ceftazidime 
or ceftriaxone showed resistance. Confirmation of ESBL pro-
duction was performed using the double disk method where 
ESBL production was considered positive when a difference of 
≥5 mm between the zone diameters of either the cephalosporin 
disks and their respective clavulanic acid combination disk was 
observed [11]. For the purposes of our analysis, we classified 
phenotypic ESBL positivity as any isolate that was resistant to 
either ceftriaxone or ceftazidime, and the ESBL activity was in-
hibited by the β-lactamase inhibitor clavulanic acid.
PCR Screening for β-lactamase Encoding Genes
We conducted a series of multiple polymerase chain reaction 
(PCR) amplifications on all Gram-negative isolates to detect 
β-lactamase genes (CTX-M, TEM, SHV, and OXA) [12–14] 
and AmpC lactamase genes (MOX, DHA, EBC, FOX, ACC, 
CIT) [15, 16] (see Supplementary Table S1). A  positive PCR 
result was determined by the detection of a PCR amplicon of 
an appropriate size for each target in the presence of appro-
priate positive and negative controls. Given that multiplex PCR 
was performed only to reveal β-lactamase groups and not the 
subvariant enzymes within each group, we defined genotypic 
ESBL positivity as any isolate that was PCR-positive for any 
CTX-M genes (CTX-M1, 2, 8, 9, or 25).
Statistical Analysis
All data are presented as counts or percentages, including the 
proportions of specific bacteria that were reported as being sus-
ceptible to various antimicrobials (which can be seen in Table 4). 
Univariate analysis was performed (SAS, Cary, NC, USA ver-
sion 9.4) to assess any potential associations between catego-
rical variables and the proportion of ESBL positivity.
RESULTS
Enrollment and sample collection was performed at study 
subjects’ first point of contact with the healthcare facility unless 
on an evening or weekend, in which case study staff enrolled 
the subject at the earliest time afterward. From 19  871 blood 
cultures collected during TSAP across 12 sub-Saharan Africa 
sites, 961 (4.8%) pathogens were isolated. For the purposes 
of this analysis, 505 Gram-negative bacteria were recovered, 
shipped, and subjected to reconfirmation at a reference labora-
tory—this accounted for 58.6% of all pathogens isolated during 
TSAP (excluding Gram-positives, unrecoverable organisms, 
and Salmonella Typhi, which were not able to be shipped due 
to exportation restrictions or other logistical issues) (Figure 1). 
The 505 pathogenic Gram-negative Enterobacteriaceae and 
non-Enterobacteriaceae were recovered from the blood of 396 
patients in 9 African countries. Multiple pathogens (≥2 path-
ogenic isolates) were isolated from the blood of 83 (21.0%) of 
396 patients. Enterobacteriaceae accounted for the majority 
423 (84.8%) of the 505 pathogenic isolates. The majority of 
pathogenic isolates were from patients enrolled in Ghana, 354 
(70.1%); followed by Madagascar, 39 (7.7%); Senegal, 33 (6.5%); 
and Burkina Faso, 27 (5.3%) of 505 (Table 1).
Using univariate analysis, we found that organisms isolated 
from infants ≤1 year of age were significantly more likely to ex-
hibit ESBL activity than those isolated from patients >1 year of 
age for the Ghana study site only (phenotype positive P = .01; 
and genotype positive P < .001, respectively) (Table 2).
All organisms were screened by disk diffusion for suscepti-
bility to ceftriaxone and ceftazidime; 136 (27%) of 505 isolates 
were resistant to ceftriaxone, ceftazidime, or both. Among these 
isolates, the activity of extended-spectrum cephalosporins was 
restored in vitro by clavulanic acid in 61 (44.9%) of 136 of these 
organisms, and these were classified to have phenotypic ESBL 
activity. Among the isolates resistant to a third generation ceph-
alosporin whose activity could be restored by clavulanic acid 
(ESBL positive-phenotype), 23 (37.7%) of 61 isolates were also 
positive for a screened ESBL gene. The highest proportions of 
ESBL phenotype-positivity were found in Klebsiella spp.  40 
(45.5%) of 88, Serratia spp. 2 (16.7%) of 12, and Acinetobacter 
spp. 6 (16.2%) of 37.
CTX-M ESBL genes were detected in 47 (9.3%) of 505 
isolates. The Ghana site yielded 41 (87.2%) ESBL genotype-
positive isolates, whereas Madagascar and Senegal each yielded 
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2 (4.3%) and Burkina Faso and Kenya each yielded 1 (2.1%) 
of 47 ESBL genotype-positive isolates, respectively. Among 
specific pathogens, ESBL genotype positivity was found in 36 
(40.9%) of 88 Klebsiella spp., 4 (14.8%) of 27 Enterobacter spp., 
and in 5 (4.1%) of 122 Escherichia coli.
Multiplex PCR screening of all 505 isolates produced 189 
amplicons associated with β-lactamase encoding genes (Table 3). 
TEM accounted for 118 (62.4%) of the 189 detected β-lactamase 
encoding genes and were mainly found in invasive nontyphoidal 
Salmonella (NTS) 69  (58.5%) and E.  coli 30  (25.4%) of 118 
isolates. Conversely, 12 (54.5%) of 22 OXA and 36 (76.6%) of 
47 CTX-M β-lactamase encoding genes were found predom-
inantly in Klebsiella spp. Overall, CTX-M β-lactamases were 
amplified in 47 (30.9%) of 152 Enterobacteriaceae; 45 (95.7%) 
of 47 belonged to the CTX-M-1 subgroup.
ESBL phenotype and genotype positivity was identified in 
7 (5.7%) and 5 (4.1%) of 122 E. coli isolates, respectively. The 
susceptibility of these E. coli against β-lactams and β-lactamase 
Table 1.  Distribution of Various Extended-spectrum β-Lactamase Gram-negative Bloodstream Isolates and Countries of Origin
Bacteria Isolated, N Burkina Faso Ethiopia Ghana Guinea-Bissau Kenyaa Madagascar Senegal Sudan Tanzania Total Isolates (%)b
Enterobacteriaceae
  Enterobacter spp. 0 0 5c 2 0 16 4 0 0 27 (5.3)
   ESBL Phenotype pos.d 0 0 0 0 0 1 0 0 0 1 (3.7)
   ESBL Genotype pos.e 0 0 2 0 0 0 2 0 0 4 (14.8)
  Escherichia coli 7 1 85c 0 0 3 15 5 6 122 (24.2)
   ESBL Phenotype pos. 2 0 5 0 0 0 0 0 0 7 (5.7)
   ESBL Genotype pos. 1 0 4 0 0 0 0 0 0 5 (4.1)
  Klebsiella spp. 0 0 77c 0 0 8 1 0 2 88 (17.4)
   ESBL Phenotype pos. 0 0 39 0 0 1 0 0 0 40 (45.5)
   ESBL Genotype pos. 0 0 34 0 0 2 0 0 0 36 (40.9)
  iNTS 12 0 118c 11 1 5 8 0 4 159 (31.5)
   ESBL Phenotype pos. 0 0 2 0 0 0 0 0 0 2 (1.3)
   ESBL Genotype pos. 0 0 1 0 1 0 0 0 0 2 (1.3)
  Serratia spp. 0 0 12 0 0 0 0 0 0 12 (2.4)
   ESBL Phenotype pos. 0 0 2 0 0 0 0 0 0 2 (16.7)
   ESBL Genotype pos. 0 0 0 0 0 0 0 0 0 0
  Proteus mirabilis 3 0 3c 0 0 0 3 5 1 15 (3.0)
   ESBL Phenotype pos. 1 0 0 0 0 0 0 0 1 2 (13.3)
   ESBL Genotype pos. 0 0 0 0 0 0 0 0 0 0
Non-Enterobacteriaceae
  Acinetobacter spp. 2 0 22 7 0 3 0 3 0 37 (7.3)
   ESBL Phenotype pos. 0 0 4 0 0 2 0 0 0 6 (16.2)
   ESBL Genotype pos. 0 0 0 0 0 0 0 0 0 0
  Burkholderia spp. 0 1 0 2 0 0 2 0 0 5 (1.0)
   ESBL Phenotype pos. 0 0 0 0 0 0 0 0 0 0
   ESBL Genotype pos. 0 0 0 0 0 0 0 0 0 0
  Pseudomonas spp. 3 0 26 0 0 0 0 0 0 29 (5.7)
   ESBL Phenotype pos. 0 0 0 0 0 0 0 0 0 0
   ESBL Genotype pos. 0 0 0 0 0 0 0 0 0 0
  Otherf 0 0 6 0 0 4 0 1 0 11 (2.2)
   ESBL Phenotype pos. 0 0 1 0 0 0 0 0 0 1 (9.1)
   ESBL Genotype pos. 0 0 0 0 0 0 0 0 0 0
Total isolates from each  
country (%)
27 (5.3) 2 (0.4) 354 (70.1) 22 (4.4) 1 (0.2) 39 (7.7) 33 (6.5) 14 (2.8) 13 (2.6) 505 (100.0)
  ESBL Phenotype pos. 
total by country (%)
3 (6.0) 0 (0) 53 (86.9) 0 (0) 0 (0) 4 (6.6) 0 (0) 0 (0) 1 (2.0) 61 (100.0)
  ESBL Genotype pos.  
total by country (%)
1 (2.1) 0 (0) 41 (87.2) 0 (0) 1 (2.1) 2 (4.3) 2 (4.3) 0 (0) 0 (0) 47 (100.0)
Abbreviation: ESBL, extended spectrum β-lactamase; iNTS, invasive non-typhoidal Salmonella spp.
aDue to logistic constraints, ONLY Salmonella spp. from the Kenya site could be analyzed.
bProportions for ESBL phenotype- and genotype-positives expressed as percentages of each specific species total.
cIncludes data that was published previously by Eibach et al [20].
dESBL phenotype-positive refers to resistance to ceftriaxone and susceptibility β-lactamase inhibitor (amoxicillin-clavulanate) OR resistance to ceftazidime and susceptibility to β-lactamase 
inhibitor (amoxicillin-clavunalate)
eESBL genotype-positive refers to pathogens expressing CTX-M genes detected by polymerase chain reaction.
fOther non-Enterobacteriaceae includes Achromobacter spp., Wautersiella spp., Stenotrophomonas spp., Pasteurella spp., Comamonas spp.
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inhibitor combinations was reduced in CTX-M PCR amplicon-
positive and some amplicon-negative E. coli as well (Table 4). 
CTX-M and OXA-expressing E. coli were 20% and 50% suscep-
tible to ciprofloxacin, respectively. However, the OXA-expressing 
organisms were susceptible to cefazolin and ceftriaxone, 
whereas the CTX-M expressing E. coli were resistant to all first-, 
third-, and fourth-generation cephalosporins. All β-lactamase 
expressing E. coli remained susceptible to carbapenems.
When compared to E. coli or iNTS, the majority of Klebsiella 
spp. isolated were resistant to cephalosporins, especially OXA 
(33% of isolates susceptible to ceftriaxone), CTX-M (22% of 
isolates susceptible to ceftriaxone), and AmpC (no susceptibility 
to ceftriaxone)-expressing strains. The proportions of CTX-M 
and OXA-expressing Klebsiella spp. susceptible to ciprofloxacin 
were 68% and 33%, respectively.
Table 2.  Age, Pretreatment, Hospital Admission, and Extended-spectrum β-Lactamase (ESBL) Status of Patients With ESBL Gram-negative Bloodstream 
Infections
All Countries Except Ghana Ghana Only
 Phenotypic Genotypic Phenotypic Genotypic
Age Group
ESBL 
Positive
ESBL  
Negative
P 
Value
ESBL 
Positive
ESBL  
Negative
P 
Value
ESBL  
Positive
ESBL  
Negative
P 
Value
ESBL  
Positive
ESBL  
Negative P Value
n n  n n  n n  n n  
0 to ≤1 yr 3 29 .246 1 31 .667 24 76 .001 27 73 <.001
>1 yr to ≤2 yrs 1 10 .560 1 10 .457 0 27 .968 0 27 .970
>2 yrs to ≤3 yrs 0 8 .977 0 8 .979 4 17 .728 1 20 .229
>3 yrs to ≤4 yrs 0 2 .988 0 2 .989 0 4 .988 0 4 .989
>4 yrs to ≤5 yrs 0 4 .984 0 4 .985 0 3 .989 0 3 .990
>5 yrs to ≤10 yrs 2 12 .134 1 13 .620 4 9 .161 2 11 .889
>10 yrs to ≤18 yrs 0 6 .980 0 6 .981 4 11 .274 4 11 .159
>18 yrs to ≤35 yrs 1 22 .829 2 21 .303 1 20 .167 1 20 .2291
>35 yrs to ≤50 yrs 0 17 .966 0 17 .667 2 15 .599 0 17 .976
>50 yrs 0 16 .967 1 15 .457 4 38 .200 2 40 .076
Total patients (%) 7 (5.3%) 126 (94.7%)  6 (4.5%) 127 (95.5%)  43 (16.3%) 220 (83.4%)  37 (14.1%) 226 (85.9%)  
Taken antimalarial prior  
to consultation
1 21 .869 1 21 .993 4 24 .755 2 26 .277
Taken antimicrobial  
prior to consultation
2 18 .317 1 19 .909 1 22 .137 2 21 .444
Admitted to hospital 3 50 .868 3 50 .606 38 197 .820 35 200 .277
Abbreviation: ESBL, extended spectrum β-lactamase.
Table 3. Distribution of β-lactamase Gene Sequences Among Gram-negative Bloodstream Isolates
Ambler Classification 
Class A Class D
TEM SHV CTX-M1 CTX-M2 CTX-M9 CTX-M8 CTX-M25 OXA
Enterobacteriaceae
 Enterobacter spp. 3 0 4 0 0 0 0 2
 Escherichia coli 30 0 5 0 0 0 0 4
 Klebsiella spp. 14 1 34 2 0 0 0 12
 iNTS 69 1 2 0 0 0 0 4
 Serratia spp. 0 0 0 0 0 0 0 0
 Proteus mirabilis 1 0 0 0 0 0 0 0
Non-Enterobacteriaceae
 Acinetobacter spp. 0 0 0 0 0 0 0 0
 Burkholderia spp. 0 0 0 0 0 0 0 0
 Pseudomonas spp. 1 0 0 0 0 0 0 0
 Othera 0 0 0 0 0 0 0 0
Total sequences 118 2 45 2 0 0 0 22
Abbreviations: CTX, cefotaxime hydrolytic activity; OXA, oxacillin hydrolytic activity; SHV, sulhydryl variable; TEM, “Temoneira” derivative.
aOther non-Enterobacteriaceae includes Achromobacter spp., Wautersiella spp., Stenotrophomonas spp., Pasteurella spp., Comamonas spp.
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Combined ESBL phenotype and genotype positivity was found 
in 2 (1.3%) of 159 iNTS isolates. Serotyping was only performed 
on 63 of the nontyphoidal Salmonella isolates. This led to 34 
Salmonella serovar Typhimurium, 15 Salmonella serovar Dublin, 
9 Salmonella serovar Enteritidis, and 5 other unknown serotypes. 
Among serotyped iNTS, one Salmonella serovar Typhimurium 
from Kenya was ESBL genotype-positive; the other iNTS ESBL 
isolates were not serotyped. None of the CTX-M iNTS isolates 
were susceptible to amoxicillin/clavulanate (Table 4), and iNTS 
susceptibility to fluoroquinolones was 95% and above for all iso-
lated strains (including CTX-M strains). All iNTS phenotypes 
were susceptible to carbapenems.
DISCUSSION
The sub-Saharan Africa genotypic ESBL prevalence of 9.3% and 
phenotypic ESBL prevalence of 12.1% from our findings appear 
to be within the lower range of other available estimates [17–19]. 
It should be of note that 354 (70.1%) of 505 total bacteria isolated 
were identified through the Asante Akim North, Ghana sur-
veillance site. Of the Ghanaian bloodstream Enterobacteriaceae 
isolates, 48 (16.0%) of 300 were ESBL phenotype-positive in-
cluding two iNTS ESBL phenotype-positive isolates, slightly 
higher than the 41 (9.7%) of 423 described by Eibach et  al 
(2016) in previous surveillance in a similar region in Ghana 
[20]. This may reflect differences in our “Enterobacteriaceae 
pathogen mix” gathered from Ghana—the total number of 
samples gathered by Eibach and colleagues contained a much 
larger proportion of ESBL-negative Salmonella enterica. That 
analysis included 215 iNTS isolates and 110 Salmonella Typhi 
isolates, whereas our analysis only included 159 iNTS isolates. 
This may be due to the facts that Eibach and colleagues addi-
tionally included isolates from 2007 to 2009 and logistical issues 
in our analysis, which did not make it possible to include any 
Salmonella serovar Typhi isolates here.
The majority of iNTS, Klebsiella spp., and E. coli isolates in 
our analysis carried TEM, CTX-M-1, and/or OXA β-lactamase 
genes. iNTS (69, 90.8% of 76)  and E.  coli (30, 76.9% of 
39)  isolates in general were found to have more TEM-type 
genes, whereas Klebsiella spp. isolates carried more OXA and 
CTX-M-type genes (Table 2). This is reflected phenotypically 
as lower proportions of Klebsiella spp. were found to be sus-
ceptible to ceftriaxone and ceftazidime compared to other 
Enterobacteriaceae (Table 4). Among the CTX-M group, the 
predominance of the CTX-M-1 subgroup could suggest the 
presence of CTX-M-15 enzyme, which is the most widely 
disseminated CTX-M ESBL enzyme [21].
Reduced susceptibility to β-lactams was often coupled with 
reduced fluoroquinolone susceptibility for E. coli and Klebsiella 
spp. isolates (Table 4). Although some clinicians may consider 
a fluoroquinolone before a carbapenem for empiric treat-
ment of ESBL bacteremia because of availability and cost, this 
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may be associated with an increased mortality even in strains 
where fluoroquinolones are reported as susceptible [22]. 
Unfortunately, this would leave parenteral carbapenems as one 
of the last viable treatment options for many affected patients 
like those identified in our surveillance.
As expected, all pathogens isolated with CTX-M genes 
were resistant to early generation cephalosporins and the 
majority of these were also resistant to extended-spectrum 
cephalosporins. This finding was expected as it is known that 
CTX-M β-lactamases have greater activity in hydrolyzing 
third- and fourth-generation cephalosporins. In contrast, 
TEM and SHV isolates (iNTS and E.  coli), which are known 
to hydrolyze penicillins and lower generation cephalosporins, 
retained susceptibility to extended-spectrum cephalosporins. 
Traditionally, OXA β-lactamases do not hydrolyze extended-
spectrum cephalosporins well, so our findings of resistance 
against antimicrobials such as cefepime and ceftazidime, par-
ticularly among iNTS, Enterobacter, and Klebsiella isolates, are 
cause for concern. Interestingly, OXA-expressing E. coli isolates 
retained susceptibility to extended-spectrum cephalosporins. 
This complicates clinicians turning to carbapenems (which 
is unlikely to be a practical choice in many underresourced 
settings) as one of the last line options for treatment against 
MDR Gram-negatives unless there are either methods avail-
able for phenotypic or genotypic ESBL identification or clin-
ical deterioration despite therapy with extended-spectrum 
cephalosporins. Our data indicate that the proportion of ESBL 
(and OXA β-lactamase) positive E.  coli and iNTS is still low; 
this, taken together with the remainder of our Gram-negative 
ESBL data, does not yet support empiric treatment with 
carbapenem agents.
ESBL positivity and age-association were analyzed separately 
for Ghana and non-Ghana sites because only children under 
15 years old were recruited in the Asante Akim North site. The 
reason for the association between age up to 1  year old and 
ESBL positivity in the Ghana site is unclear—to our knowledge 
there has been no association found to date linking infants of 
young age to ESBL positivity. Many clinical and demographic 
data that would have shed light on this association were either 
missing or not collected as a part of surveillance. It is also pos-
sible that associations between other age groups and ESBL posi-
tivity exist, but our study was not powered to detect them.
Our findings reveal further data on the distribution of AMR 
in sub-Saharan Africa. Previous data from Africa suggest that 
the proportion of ESBL producing bloodstream isolates can 
be quite variable; perhaps the most comprehensive review 
of ESBLs in Africa (13 countries) was performed by Tansarli 
et al in 2013, which reported 0.7–75.8% of Enterobacteriaceae 
to be ESBL producing isolates in bloodstream infections [19]. 
However, none of these sources reported in detail both gen-
otypic and phenotypic data for ESBL isolates. In general, our 
findings indicate that >1 out of 10 (12.1%) of Gram-negative 
pathogens are ESBL phenotype positive. Moreover, because 
blood samples were collected at the subjects’ first point of con-
tact with the healthcare facility, it can be inferred that all isolates 
were community-acquired. ESBL phenotype positivity was not 
limited to any specific pathogen within the Enterobacteriaceae 
family and also included non-Enterobacteriaceae such as 
Acinetobacter. Although these pathogens may have benefitted 
from prompt treatment with carbapenems, capacities of micro-
biology laboratories should be first prepared to perform phe-
notypic ESBL screening and confirmatory testing as a tool to 
promote antimicrobial stewardship and prevent untoward em-
piric use of carbapenems, which are expensive and broad-spec-
trum in their activity.
Our study has several limitations. First, in certain surveil-
lance settings, there were some patients included in this analysis 
who were enrolled without meeting the TSAP inclusion criteria, 
which may have compromised the homogeneity of sample col-
lection and the generalizability of results. This was rationalized 
because it was not ethically acceptable to withhold access to 
blood culture for patients who would benefit from the test. 
Second, we were not able to report the genotypic subvariants 
within TEM, CTX-M, SHV, and OXA groups at the time of 
writing. Therefore, we counted all isolates with non-CTX-M 
gene groups as ESBL genotype-negative, and it is possible that 
this could have underestimated true ESBL genotype-positivity. 
Genome sequencing work is being performed on isolates from 
surveillance that will reveal genotypic variants. Third, logistic 
challenges limited our analyses to the pathogens that were able 
to be received at the reference laboratory. Although such data 
would have been of importance, we were unfortunately not able 
to perform any ESBL analyses on Salmonella Typhi or Paratyphi 
isolates due to these challenges. For this reason, the 505 isolates 
included in these analyses may not necessarily be representa-
tive of the pathogen mix or distribution of pathogens for each 
country.
In summary, our findings are broadly consistent with the 
sparse ESBL data available and reveal ESBL production in a 
substantial minority of pathogenic Gram-negative bloodstream 
isolates collected from sentinel surveillance sites in sub-Saharan 
Africa. Resistance to ESBL agents may have particular relevance 
for guidelines such as IMCI, which outline the empiric man-
agement of febrile illnesses and suspected septicemia. Our data 
suggest that in >1 in 10 Gram-negative bloodstream isolates, 
Carbapenems may be one of the last susceptible alternatives 
even though these agents are expensive, not readily avail-
able, and must be administered parenterally. The prevalence 
of ESBL bloodstream pathogens requiring carbapenems as 
first-line agents in resource-limited settings should be a great 
cause for concern, not only for the factors just mentioned 
but also because it may lead to the more serious problem of 
carbapenemase-producing Enterobacteriaceae. To this end, in-
tegrated antimicrobial stewardship measures become even more 
S458 • cid 2019:69 (Suppl 6) • Toy et al
paramount to ameliorate the burden of AMR. Although much 
work needs to be done to develop new classes of antimicrobials, 
control strategies must also be integrated with improved water 
and sanitation as well as vaccines (such as newly available ty-
phoid conjugate vaccines) where applicable.
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